About this item:

44 Views | 24 Downloads

Author Notes:

Laurence W. Busse, Email: lbusse@emory.edu

All authors were major contributors in writing the manuscript and approved the final manuscript.

The authors declare that they have no competing interests.

Subjects:

Research Funding:

No funding sources declared.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Critical Care Medicine
  • General & Internal Medicine
  • Vasoplegic syndrome
  • Shock
  • De-catecholaminization
  • Hydroxocobalamin
  • Angiotensin II
  • Cardiopulmonary bypass
  • NITRIC-OXIDE SYNTHASE
  • SYSTEMIC INFLAMMATORY RESPONSE
  • CARDIOPULMONARY BYPASS SIRS
  • ADULT CARDIAC-SURGERY
  • METHYLENE-BLUE
  • DOUBLE-BLIND
  • VITAMIN-C
  • VASOPRESSOR THERAPY
  • SEVERE SEPSIS
  • SEPTIC SHOCK

Vasoplegic syndrome following cardiothoracic surgery-review of pathophysiology and update of treatment options

Tools:

Journal Title:

Critical Care Nursing Quarterly

Volume:

Volume 24, Number 1

Publisher:

, Pages 36-36

Type of Work:

Article | Final Publisher PDF

Abstract:

Vasoplegic syndrome is a common occurrence following cardiothoracic surgery and is characterized as a high-output shock state with poor systemic vascular resistance. The pathophysiology is complex and includes dysregulation of vasodilatory and vasoconstrictive properties of smooth vascular muscle cells. Specific bypass machine and patient factors play key roles in occurrence. Research into treatment of this syndrome is limited and extrapolated primarily from that pertaining to septic shock, but is evolving with the expanded use of catecholamine-sparing agents. Recent reports demonstrate potential benefit in novel treatment options, but large clinical trials are needed to confirm.

Copyright information:

© 2020 The Author(s).

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote